A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features

Table 2 Early adverse events related ^a to treatment (≥10%) per patient (%) according to NCI-CTC criteria v3.0

Note: there were no grade 4 events.
^aAn adverse event was considered attributable to bevacizumab, capecitabine or radiation if it was deemed remotely, possibly or probably related.

ISSN: 1471-2407